{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:42:50Z","timestamp":1790048570454,"version":"4.0.1"},"reference-count":54,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reviews in Medical Virology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>HTLV infection appears to be more common among renal transplant candidates than in the related general population. HTLV\u20101\u2010associated diseases may occur in carriers who are transplanted but there is insufficient evidence to confirm whether these occur more frequently as a result of the associated immunosuppression. Consequently, pre\u2010existing HTLV\u20101 infection should not be considered a contra\u2010indication to transplantation.<\/jats:p>\n                  <jats:p>The risk of transmission of HTLV\u20101 through solid organ transplantation from a confirmed infected donor is unknown. There are anecdotes of multiple infections from a single donor. Biologically due to the significant volume of blood and the lack of storage, transmission would be expected to be higher than following blood transfusion. The rate of subsequent disease is unknown, but there are now 11 reports of HAM and 2 of ATL occurring within 4\u00a0years of transplantation associated infection. There are insufficient data to know whether the time from infection to onset of disease and the rate of progression differ from transmission through other routes, but early onset and rapid progression is a concern. Responses to enhanced immunosuppression for the treatment of HAM are variable.<\/jats:p>\n                  <jats:p>The risk of HTLV\u20101 associated disease in exchange for a life\u2010saving major organ transplantation from an infected donor might be considered worth taking by some HTLV\u20101 uninfected patients. Peri\u2010transplantation antiretroviral prophylaxis with zidovudine and raltegravir is biologically sound but therapeutically unproven. The risks related to HTLV\u20101 infection appear to preclude the use of any other tissue. All transplant donors should be screened for HTLV\u20101 infection regardless of perceived risk.<\/jats:p>","DOI":"10.1002\/rmv.1970","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T23:06:37Z","timestamp":1517267197000},"source":"Crossref","is-referenced-by-count":34,"title":["Human T\u2010lymphotropic virus type 1 infection and solid organ transplantation"],"prefix":"10.1002","volume":"28","author":[{"given":"Graham P.","family":"Taylor","sequence":"first","affiliation":[{"name":"Professor of Human Retrovirology, Department of Medicine Imperial College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.12.7415"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.6.2031"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)92200-0"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(84)90446-X"},{"key":"e_1_2_4_6_1","unstructured":"IARC monographs on the evaluation of carcinogenic risk to humans: human immunodeficiency viruses and human T\u2010cell lymphotropic viruses lyon:IARC;1996[Available from:http:\/\/monographs.iarc.fr\/ENG\/Monographs\/vol67\/index.php]."},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)92734-5"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)91298-5"},{"issue":"8498","key":"e_1_2_4_9_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(86)91636-3","article-title":"Blood transfusion and HTLV\u2010I associated myelopathy","volume":"2","author":"Osame M","year":"1986","journal-title":"Lancet"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280110"},{"issue":"1","key":"e_1_2_4_11_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/167.1.57","article-title":"Heterosexual transmission of human T cell leukemia\/lymphoma virus type I among married couples in southwestern Japan: an initial report from the Miyazaki cohort study","volume":"167","author":"Stuver SO","year":"1993","journal-title":"J Infect Dis"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171303"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30252-3"},{"key":"e_1_2_4_14_1","article-title":"Early onset of HTLV\u20101 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) and adult T\u2010cell leukemia\/lymphoma (ATL): systematic search and review","author":"Oliveira PD","year":"2017","journal-title":"J Trop Pediatr"},{"issue":"12","key":"e_1_2_4_15_1","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/jnnp.2009.191239","article-title":"A 15\u2010year prospective longitudinal study of disease progression in patients with HTLV\u20101 associated myelopathy in the UK","volume":"81","author":"Martin F","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1994.34694295061.x"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199002083220607"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19871001)60:7<1474::AID-CNCR2820600712>3.0.CO;2-Y"},{"issue":"3","key":"e_1_2_4_19_1","first-page":"105","article-title":"The seroprevalence of hepatitis and retroviral infection in Jamaican haemodialysis patients","volume":"47","author":"Barton EN","year":"1998","journal-title":"West Indian Med J"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(05)80036-8"},{"issue":"3","key":"e_1_2_4_21_1","first-page":"187","article-title":"Seroepidemiology of human T\u2010cell lymphotropic virus 1 infection in hemodialysis patients: should we be concerned about it?","volume":"7","author":"Ghaffari J","year":"2013","journal-title":"Iran J Kidney Dis"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(89)80091-5"},{"issue":"3","key":"e_1_2_4_23_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00126334-199911010-00018","article-title":"Seroprevalence of HTLV\u2010I\/II antibodies in blood donors and different groups at risk in Tunisia","volume":"22","author":"Mojaat N","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04037.x"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1125>3.0.CO;2-N"},{"key":"e_1_2_4_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000235186.30113.c7"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.345"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.03.132"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2011.11.021"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.2950"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(00)00332-4"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40111421.x"},{"issue":"7","key":"e_1_2_4_33_1","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/01.TP.0000058470.15921.CA","article-title":"Human T\u2010 Cell leukemia virus type I infection in various recipients of transplants from the same donor","volume":"75","author":"Gonzalez\u2010Perez MP","year":"2003","journal-title":"Transplantation"},{"issue":"1","key":"e_1_2_4_34_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12977-015-0236-7","article-title":"Rapid dissemination of human T\u2010lymphotropic virus type 1 during primary infection in transplant recipients","volume":"13","author":"Cook LB","year":"2016","journal-title":"Retrovirology"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit545"},{"issue":"6","key":"e_1_2_4_36_1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/jnnp.71.6.818","article-title":"Lymphotropic virus type I (HTLV\u20101) associated myelopathy acquired through a liver transplant","volume":"71","author":"Zarranz JJ","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200301150-00019"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.09.010"},{"key":"e_1_2_4_39_1","first-page":"4203079","article-title":"Two cases of human T\u2010lymphotropic virus type I\u2010associated myelopathy\/tropical spastic paraparesis caused by living\u2010donor renal transplantation","volume":"2016","author":"Tajima Y","year":"2016","journal-title":"Case Rep Neurol Med"},{"key":"e_1_2_4_40_1","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215243","article-title":"HTLV\u20101\u2010associated myelopathy in a solid organ transplant recipient","volume":"2016","author":"Montesdeoca Andrade MJ","year":"2016","journal-title":"BMJ Case Rep"},{"key":"e_1_2_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12849"},{"key":"e_1_2_4_42_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2002.20712.x"},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2007.00225.x"},{"issue":"4","key":"e_1_2_4_44_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ajt.12127","article-title":"Human T cell lymphotrophic virus 1\/2 in solid organ transplantation","volume":"13","author":"Kaul DR","year":"2013","journal-title":"Am J Transplant"},{"key":"e_1_2_4_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13141"},{"key":"e_1_2_4_46_1","unstructured":"European Centre for Disease Prevention and Control.Risk assessment of HTLV\u20101\/2 transmission by tissue\/cell transplantation: Part 1 epidemiological review. Stockholm;2011. Accessed May 14 2011."},{"key":"e_1_2_4_47_1","unstructured":"European Centre for Disease Prevention and Control.Geographical distribution of areas with a high prevalence of HTLV\u20101 infection. Stockholm;2015."},{"key":"e_1_2_4_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12105"},{"key":"e_1_2_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)00261-9"},{"key":"e_1_2_4_50_1","doi-asserted-by":"publisher","DOI":"10.1086\/376531"},{"issue":"2","key":"e_1_2_4_51_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1172\/JCI113085","article-title":"Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I","volume":"80","author":"Matsushita S","year":"1987","journal-title":"J Clin Investig"},{"key":"e_1_2_4_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01413-10"},{"issue":"1","key":"e_1_2_4_53_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-4690-3-63","article-title":"Zidovudine plus lamivudine in human T\u2010lymphotropic virus type I\u2010associated myelopathy: a randomised trial","volume":"3","author":"Taylor G","year":"2006","journal-title":"Retrovirology"},{"issue":"5","key":"e_1_2_4_54_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3390\/v3050469","article-title":"Susceptibility of primary HTLV\u20101 isolates from patients with HTLV\u20101\u2010associated myelopathy to reverse transcriptase inhibitors pre\u2010 and post\u2010 sustained in vivo therapy","volume":"3","author":"Macchi B","year":"2011","journal-title":"Virus"},{"key":"e_1_2_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(90)90172-6"}],"container-title":["Reviews in Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frmv.1970","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rmv.1970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T23:45:46Z","timestamp":1751240746000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/rmv.1970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,29]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/rmv.1970"],"URL":"https:\/\/doi.org\/10.1002\/rmv.1970","archive":["Portico"],"relation":{},"ISSN":["1052-9276","1099-1654"],"issn-type":[{"value":"1052-9276","type":"print"},{"value":"1099-1654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,29]]},"article-number":"e1970"}}